Immuneering (IMRX) said Thursday it has priced its underwritten public offering of about 19 million shares at $9.23 each to raise gross proceeds of about $175 million.

The company said underwriters have also been granted a 30-day option to purchase up to an additional 2.8 million shares at the same price, excluding discounts and commissions.

Additionally, the company said Sanofi (SNY) has agreed to purchase 2.7 million shares at the same price in a private placement set to close concurrently with the public offering.

Proceeds from both the offering and private placement, expected to close Friday, will be used to support preclinical and clinical development of Immuneering's drug candidates, as well as for general corporate purposes, it added.